Related Experiment Video
Updated: Aug 10, 2026
06:46
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
[Behavioral pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD): Spanish validation]
M Boada1, L Tárraga, G Modinos
1Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona. mboada@fundacioace.com
Neurologia (Barcelona, Spain)
|March 10, 2006
Summary
The Spanish version of the Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) effectively screens for neuropsychiatric symptoms in dementia patients. This validated tool aids clinicians in routine practice for Alzheimer's patients.
Area of Science:
- Neuroscience
- Gerontology
- Psychiatry
Context:
- Alzheimer's disease (AD) presents significant behavioral disturbances.
- Screening tools are crucial for early detection and management of these symptoms.
- The Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) is a key instrument for evaluating behavioral pathology in AD.
Purpose:
- To validate the Spanish version of the BEHAVE-AD for routine clinical use.
- To assess the reliability and accuracy of the BEHAVE-AD in a Spanish-speaking dementia population.
- To establish the BEHAVE-AD as a viable screening tool in clinical practice.
Summary:
- The BEHAVE-AD Spanish version was cross-validated against the Neuropsychiatric Inventory-Questionnaire (NPI-Q) in 79 nursing-home patients with dementia.
- Moderate to significant correlations were found between the BEHAVE-AD and NPI-Q (r=0.694 for overall scores, r=0.698 for symptoms/severity, and r=0.535 for caregiver disturbance/distress).
- Concurrent validity was further supported by comparisons with the Cohen-Mansfield Agitation Inventory (CMAI) and Hamilton Depression Rating Scale (HDRS).
Impact:
- The validated Spanish BEHAVE-AD facilitates early detection of neuropsychiatric symptoms in dementia patients.
- This tool enhances clinical practice by providing a reliable screening method for Spanish-speaking populations.
- It supports improved patient care and management strategies for behavioral disturbances in Alzheimer's disease.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...